Actinium Pharmaceuticals, Inc. announced the appointment of Niva Almaula as Chief Business Officer, effective immediately. Dr. Almaula joins Actinium with significant experience in the targeted radiotherapy field, having most recently worked as Head, Business Development at Advanced Accelerator Applications, Inc. As Chief Business Officer, Dr. Almaula will be focused on leading partnership, licensing and collaboration activities for Actinium's clinical-stage ARC's or Antibody Radiation Conjugates for targeted conditioning including Iomab-B, Actimab-MDS and the Iomab-ACT program, its ARC therapeutics and combinations and AWE or Antibody Warhead Enabling technology platform that is being utilized in a collaborative research partnership by Astellas Pharma, Inc.